Skip to main content

Research Repository

Advanced Search

All Outputs (44)

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): Study protocol for a multi-centre, open-label, randomised, phase II platform trial (2024)
Journal Article
Mcilroy, G., Lax, S., Gaskell, C., Jackson, A., Rhodes, M., Seale, T., …Bishton, M. (in press). Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): Study protocol for a multi-centre, open-label, randomised, phase II platform trial. BMC Cancer,

Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma (2024)
Journal Article
Bishton, M. J., Crooks, C. J., Card, T. R., & West, J. (2024). Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma. British Journal of Haematology, https://doi.org/10.1111/bjh.19371

To address the lack of contemporary population-based epidemiological studies of hepatosplenic T-cell lymphoma (HSTCL), we undertook a population-based study of ICD-O-3-coded HSTCL in England. We used the National Cancer Registration Dataset and linke... Read More about Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.

Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline (2023)
Journal Article
Cox, M. F., Mackenzie, S., Low, R., Brown, M., Sanchez, E., Carr, A., …Manson, J. J. (2024). Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline. The Lancet Rheumatology, 6(1), e51-e62. https://doi.org/10.1016/s2665-9913%2823%2900273-4

Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome characterised by persistently activated cytotoxic lymphocytes and macrophages, which, if untreated, leads to multiorgan dysfunction and death. HLH should be considered in any a... Read More about Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article
Shotton, R., Broadbent, R., Alchawaf, A., Mohamed, M. B., Gibb, A., Martinez-Calle, N., …Linton, K. (2023). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Advances, https://doi.org/10.1182/bloodadvances.2023011305

Introduction: Bendamustine is among the most effective chemotherapeutics for indolent B-cell non-Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom (2023)
Journal Article
Minson, A., Hamad, N., Di Ciaccio, P., Talaulikar, D., Ku, M., Ratnasingam, S., …Dickinson, M. (2024). Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. British Journal of Haematology, 204(2), 548-554. https://doi.org/10.1111/bjh.19179

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterised by a heterogeneous clinical course. Patients can often receive sequential treatments, yet these typically yield diminishing periods of disease control, raising questions about... Read More about Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article
Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., …Pophali, P. A. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, https://doi.org/10.1200/JCO.23.00365

PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexate... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018 (2023)
Journal Article
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T., …Crooks, C. (2023). 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018. Journal of Hematology and Oncology, 16, Article 56. https://doi.org/10.1186/s13045-023-01434-4

Haemophagocytic lymphohistiocytosis (HLH) is a lethal syndrome of excessive immune activation. We undertook a nationwide study in England of all cases of HLH diagnosed between 2003 and 2018, using linked electronic health data from hospital admission... Read More about 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018.

Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing (2023)
Journal Article
Arulogun, S. O., Brian, D., Goradia, H., Cooney, A., Menne, T., Koo, R., …D’Sa, S. P. (2023). Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing. American Journal of Hematology, 98(5), 750-759. https://doi.org/10.1002/ajh.26895

Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinaemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well established, and the impact of its use in different t... Read More about Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing.

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance (2023)
Journal Article
Barraclough, A., England, J. T., Villa, D., Wight, J., Hapgood, G., Conn, J., …Hawkes, E. A. (2023). Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. Haematologica, 108(9), https://doi.org/10.3324/haematol.2022.281375

Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between ‘low-grade’ (Grade 1, 2 and 3A FL) and diffuse large B-cell lymphoma (DLBCL) appearing to share features with each. Clinical characteristics a... Read More about Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.

Haematology (2023)
Book Chapter
Richardson, R., & Ellis, R. (2023). Haematology. In General Medicine and Surgery: Medical student revision guide (59-81). (1). Scion Publishing

Review for "Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims database" (2023)
Other
Dote, S., Inose, R., Goto, R., Kobayashi, Y., & Muraki, Y. (2023). Review for "Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims database"

Bendamustine has a potent immunosuppressive effect because it causes T-cell lymphopenia, which might lead to a second primary malignancy (SPM) and would increase the risk of infection. Using the Medical Data Vision administrative claims database, we... Read More about Review for "Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims database".

Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018 (2022)
Journal Article
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T. R., …Crooks, C. J. (2022). Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018. HemaSphere, 6(11), Article e797. https://doi.org/10.1097/HS9.0000000000000797

Hemophagocytic lymphohistiocytosis (HLH) is rare, results in high mortality, and is increasingly being diagnosed. We aimed to quantify the incidence of diagnosed HLH and examine temporal trends in relation to age and associated diseases. Using nation... Read More about Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018.

Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors (2022)
Journal Article
Bishton, M., Crooks, C., Liu, H., Ban, L., Bythell, M., Card, T., …West, J. (2022). Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors. Blood, 140(Supplement 1), 2599-2600. https://doi.org/10.1182/blood-2022-158999

Background: Haemophagocytic Lymphohistiocytosis (HLH) is a rare, life-threatening hyper-inflammatory syndrome triggered by constitutive and acquired risk factors including haematological malignancy, infection, auto-immunity and rheumatological diseas... Read More about Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors.

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe (2022)
Journal Article
Bishton, M. J., Salles, G., Golfier, C., Knauf, W., Bocchia, M., Turner, D., …Laribi, K. (2023). Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe. eJHaem, 4(1), 45-54. https://doi.org/10.1002/jha2.593

The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in patients with DLBC... Read More about Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe.

Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 (2022)
Journal Article
Liu, H., Stiller, C. A., Crooks, C. J., Rous, B., Bythell, M., Broggio, J., …West, J. (2022). Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019. British Journal of Haematology, 199(5), 728-738. https://doi.org/10.1111/bjh.18459

This analysis is the largest population-based study to date to provide contemporary and comprehensive epidemiological estimates of all third edition of the International Classification of Diseases for Oncology (ICD-O-3) coded Langerhans cell histiocy... Read More about Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019.

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (2022)
Journal Article
Nastoupil, L., Morschhauser, F., Scholz, C. W., Bishton, M., Yoon, S., Giri, P., …Bartlett, N. L. (2022). P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere, 6(S3), 1015-1016. https://doi.org/10.1097/01.HS9.0000847368.92731.fb